Kemaloğlu Öz, TuğbaAbdelnabi, MahmoudFiore, CorradoAlmaghraby, AbdallahCihan, DenizBabazade, Nigar2021-11-102021-11-102021Öz, T. K., Abdelnabi, M., Fiore, C., Almaghraby, A., Cihan, D., Babazade, N., Haseeb Raza Naqvi, S., Omar, B., & Dağdeviren, B. (2021). Assessment of sacubitril/valsartan effects on left ventricular dynamics using 3D echocardiography and 3D strain in heart failure with reduced ejection fraction patients. Minerva cardiology and angiology, 10.23736/S2724-5683.21.05802-6. Advance online publication. https://doi.org/10.23736/S2724-5683.21.05802-6https://doi.org/10.23736/S2724-5683.21.05802-6https://hdl.handle.net/20.500.12713/2215BACKGROUND: Three-dimensional (3D) echocardiography and 3D strain parameters have been used for a comprehensive quantitative assessment of left ventricular (LV) myocardial dynamics. So far, there are no data on sacubitril/valsartan effects on cardiac functions and LV reverse remodeling using 3D echocardiography. This study aimed to evaluate the effects of sacubitril/valsartan on the LV functions using two-dimensional (2D) echocardiography, 3D echocardiography, and the 3D strain parameters. METHODS: A single-center prospective cohort study which included 100 heart failure with reduced ejection fraction (HFrEF) patients with guidelines-approved indications for sacubitril/valsartan treatment. Patients received a short course (3-month) of sacubitril/valsartan. 3-month follow-up 2D, 3D echocardiographic parameters, and 3D strain were compared to baseline parameters. RESULTS: The results of the study revealed a significant improvement in left ventricular dynamic functions at 3-month follow-up with an improvement in left ventricular systolic function (mean left ventricular ejection fraction (LVEF) increased from 27.65 ± 4.98% to 32.89 ± 6.03%, P<0.001). Comparison of HFrEF patients with ischemic and non-ischemic etiologies showed that echocardiographic parameters significantly improved in both groups after 3 months of sacubitril/valsartan treatment. There was no statistically significant difference between both groups regarding echocardiographic parameters at baseline and 3-month follow-up. CONCLUSIONS: In a single-center prospective observational cohort study evaluating the effects of short-term (3-month course) sacubitril/valsartan treatment on LV dynamics assessed by 3D echocardiography and 3D strain, sacubitril/valsartan was associated with a significant improvement of LV systolic functions and reverse remodeling effects in both ischemic and non-ischemic HFrEF patients.eninfo:eu-repo/semantics/closedAccessHeart Failure With Reduced Ejection Fraction (HFrEF)Sacubitril/valsartan3D Echocardiography3D StainVentricular RemodelingArticle34713680WOS:0009681893000042-s2.0-85135419373Q410.23736/S2724-5683.21.05802-6N/A